Brief: Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
04/06/2024 13:39
June 4 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2
STUDY OF
EQ101 IN ALOPECIA AREATA
* EQUILLIUM INC: EQ101 WAS WELL TOLERATED IN SUBJECTS WITH
ALOPECIA AREATA WITH NO SERIOUS ADVERSE EVENTS REPORTED
Source text for Eikon: ID:nBwbss9y5a
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations